Pentamidine Isethionate Suppliers & Bulk Manufacturers
Available Forms: Injection / Inhalation solution
Available Strengths: 300 mg
Reference Brands: Pentam (USA), Nebupent (USA)
Category:
Critical Care
Pentamidine Isethionate is available in Injection / Inhalation solution
and strengths such as 300 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Pentamidine Isethionate is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Pentamidine Isethionate can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Primidone is a well-established barbiturate-derived anticonvulsant medication used in the management of epilepsy and certain movement disorders. It is widely prescribed for the treatment of partial seizures and generalized seizures, including tonic-clonic seizures, and is also effective in the management of essential tremor. Marketed under various brand names, including Mysoline, primidone has remained an important therapeutic option for patients who require long-term seizure control or tremor reduction.
Clinically, primidone plays a significant role in the comprehensive management of complex, partial, and generalized seizures. Its antiepileptic activity is primarily mediated through its active metabolites, phenobarbital and phenylethylmalonamide, which enhance inhibitory neurotransmission in the central nervous system and help suppress abnormal neuronal firing. This mechanism contributes to stabilization of neuronal membranes and reduction in seizure frequency and severity.
Primidone therapy requires careful consideration of indications, contraindications, and potential adverse effects. It is commonly initiated at low doses and gradually titrated to achieve optimal therapeutic response while minimizing side effects such as sedation, dizziness, ataxia, nausea, and fatigue. Long-term use may require periodic monitoring due to the potential for hepatic, hematologic, or neurocognitive effects. Contraindications include hypersensitivity to barbiturates and caution is advised in patients with hepatic impairment, respiratory disorders, or a history of substance dependence.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing